QVAR REDIHALER
ICS MDI
Beclomethasone dipropionate · Teva Pharmaceuticals
Active Medication & Mechanism
- Beclomethasone dipropionate ICS40 mcg or 80 mcg per actuation
Pro-drug ICS that is converted to active metabolite beclomethasone-17-monopropionate (17-BMP) in the lungs. Provides potent anti-inflammatory activity, reducing inflammatory cells and mediators in the airways. HFA formulation delivers extrafine particles for enhanced small airway deposition.
FDA-Approved Dosing by Indication
// approval varies by strength + age Asthma
3/4 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 40 mcg | Patients ≥12 years (previously on bronchodilators alone) | 1 inhalation twice daily Starting dose for patients on bronchodilators alone. | 80 mcg | FDA Approved |
| 80 mcg | Patients ≥12 years (previously on ICS) | 1 inhalation twice daily For patients previously on ICS. Maximum dose: 320 mcg/day. | 160 mcg | FDA Approved |
| 80 mcg | Patients ≥12 years (previously on oral steroids) | 2 inhalations twice daily Maximum recommended dose. | 320 mcg | FDA Approved |
| Any strength | Acute bronchospasm | — | — | Not Approved Not a bronchodilator. Not for acute bronchospasm. Use a SABA. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute use. Use a SABA. |